Literature DB >> 17890465

Comparison of high-frequency chest wall oscillation with differing waveforms for airway clearance in cystic fibrosis.

Robert R Kempainen1, Cynthia B Williams, Ann Hazelwood, Bruce K Rubin, Carlos E Milla.   

Abstract

BACKGROUND: High-frequency chest wall oscillation (HFCWO) is commonly used by cystic fibrosis (CF) patients for airway clearance. The primary objective of this study was to determine whether the use of a newer HFCWO device that generates oscillations with a triangular waveform results in greater sputum production than a commonly used device that generates oscillations with a sine waveform.
METHODS: This was a controlled, randomized, double-blind, crossover study. Fifteen clinically stable, adult CF patients participated. Patients performed airway clearance with each device once and at matched oscillation frequencies and pressures. All sputum produced during each session was collected. Patients completed pulmonary function tests before and after each session, and rated the comfort of the two devices.
RESULTS: Mean sputum wet and dry weight produced during sine waveform and triangular waveform HFCWO sessions did not differ (p = 0.11 and p = 0.2, respectively). Mean changes in FEV(1) and FVC following HFCWO therapy were also comparable (p = 0.21 and p = 0.56, respectively). However, there was a significant reduction in air trapping by residual volume/total lung capacity ratio following triangular waveform HFCWO (p = 0.01). In addition, in vitro cough transportability was 10.6% greater following therapy with the triangular waveform device (p = 0.05). Patients perceived the two devices as equally comfortable (p = 0.8).
CONCLUSIONS: Single-session sputum production is comparable with sine and triangular waveform HFCWO devices. Longer term comparisons are needed to determine whether sustained use of the devices results in clinically important differences in outcomes.

Entities:  

Mesh:

Year:  2007        PMID: 17890465     DOI: 10.1378/chest.07-1078

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  8 in total

1.  Oscillating devices for airway clearance in people with cystic fibrosis.

Authors:  Lisa Morrison; Stephanie Milroy
Journal:  Cochrane Database Syst Rev       Date:  2020-04-30

Review 2.  Oscillating devices for airway clearance in people with cystic fibrosis.

Authors:  Lisa Morrison; Stephanie Innes
Journal:  Cochrane Database Syst Rev       Date:  2017-05-04

Review 3.  Role of mechanical stress in regulating airway surface hydration and mucus clearance rates.

Authors:  Brian Button; Richard C Boucher
Journal:  Respir Physiol Neurobiol       Date:  2008-06-08       Impact factor: 1.931

4.  Chest high-frequency oscillatory treatment for severe atelectasis in a patient with toxic epidermal necrolysis.

Authors:  Shiara Ortiz-Pujols; Laura A Boschini; Cristine Klatt-Cromwell; Kathy A Short; James Hwang; Bruce A Cairns; Samuel W Jones
Journal:  J Burn Care Res       Date:  2013 Mar-Apr       Impact factor: 1.845

5.  Mesoscopic modeling as a starting point for computational analyses of cystic fibrosis as a systemic disease.

Authors:  Eberhard O Voit
Journal:  Biochim Biophys Acta       Date:  2013-04-06

6.  A pilot study of the impact of high-frequency chest wall oscillation in chronic obstructive pulmonary disease patients with mucus hypersecretion.

Authors:  Indranil Chakravorty; Kamaljit Chahal; Gillian Austin
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2011-12-14

7.  Safety and effectiveness of the high-frequency chest wall oscillation vs intrapulmonary percussive ventilation in patients with severe COPD.

Authors:  Antonello Nicolini; Bruna Grecchi; Maura Ferrari-Bravo; Cornelius Barlascini
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2018-02-16

8.  Effectiveness of treatment with high-frequency chest wall oscillation in patients with bronchiectasis.

Authors:  Antonello Nicolini; Federica Cardini; Norma Landucci; Sergio Lanata; Maura Ferrari-Bravo; Cornelius Barlascini
Journal:  BMC Pulm Med       Date:  2013-04-04       Impact factor: 3.317

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.